Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease
Robert N. Baldassano(Children's Hospital of Philadelphia), Harland S. Winter(Harvard University), David F. Hendricks, Kimberly L. DeWoody(Children's Hospital of Philadelphia), Christian Braegger(University Children's Hospital Zurich), Gregory F. Keenan, Johanna C. Escher(Erasmus MC - Sophia Children’s Hospital)
Cited by 183
Related Papers
Human gut microbiome viewed across age and geography
|Nature|2012|7.9k
Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes
|Science|2011|6.6k
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents
|Journal of Pediatric Gastroenterology and Nutrition|2013|1.4k